drugset / Trial / NCT04317300

Feasibility of Treatment for Vaping Cessation

NCT04317300

Phase 0 Withdrawn Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

Researchers are gathering information on the feasibility of treating e-cigarette users with 12-weeks of varenicline (Chantix®) in assisting with stopping the use of e-cigarettes.

Timeline

Start
2023-02-01
Primary completion
2023-02-01
Completion
2023-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1 mg

Indications

No indication recorded.